FROM THE NEWS FEED
This open-label Phase II trial (n=100) will study the safety, tolerability, and potential therapeutic effects of psilocybin (2 x 25 mg oral doses, taken at least 3 weeks apart) in the biological children of genocide survivors who are living with mood and anxiety disorders.
Continue to the original publication for the complete article.
KEEP EXPLORING
The study linked LSDβs slow dissociation from 5-HT2A receptors to prolonged Ξ²-arrestin signalling and antidepressant-...
Helus Pharma reported continued development of HLP003 for adjunctive treatment of major depressive disorder and HLP00...
The in vitro studies indicated favourable intestinal absorption, systemic exposure, metabolic stability across specie...
Psychedelics are no magic wand or silver bullet. However, in partnership with talk therapy, physical therapy, and oth...
Hereβs what first time journeyers are saying about their psychedelic experience, in partnership with Psychedelic Pass...
Hereβs what first time journeyers are saying about their psychedelic experience, in partnership with Psychedelic Pass...
There are many factors that can affect your journey, from set and setting to substance and dosage. At Psychedelic Pas...
Personal growth is a lifelong process. We've heard from so many people that, after years of other avenues, a psychede...
Again and again, we find that psychedelics can be the missing element that help people to heal and recover from past ...